Fort Collins, Colorado-based biopharmaceutical company PhotonPharma announced the closing of a $2.5 million seed financing round.
This funding will support the Phase I clinical trial of Innocell, an innovative therapy for the treatment of advanced ovarian cancer. In February 2024, PhotonPharma received FDA clearance to initiate clinical development of Innocell. The Phase I trial—expected to enroll its first patient in Q4 2024—will be a major step in evaluating the safety and efficacy of this promising new treatment.
Launched in 2018, PhotonPharma is dedicated to pioneering novel drug delivery systems and targeted treatments to improve cancer care. The company’s commitment to scientific excellence positions it at the forefront of cancer therapeutics.
KEY QUOTES:
“This funding is a significant milestone for PhotonPharma and marks a pivotal moment in our mission to advance breakthrough therapies for cancer therapies. We are excited to move forward with our clinical trials and are grateful for the support of our investors, whose confidence will help drive the development of our technology platform forward.”
– Dr. Terry Opgenorth, Chairman of the Board of Directors of PhotonPharma
“We invite investors and industry partners to attend our presentation at the Rocky Mountain Life Sciences Investor and Partnering Conference in September. It’s an excellent opportunity to learn about the development of our cutting-edge technology and the development plans for the company and its technology platform.”
– Dr. Alan Rudolph, CEO of PhotonPharma
